Last reviewed · How we verify
NCT07224386: BioDigit MG-02
Multi-Modal Monitoring of Disease Symptoms in Myasthenia Gravis
trial in Myasthenia Gravis in 50 participants. Not yet recruiting.
31 December 2027
Quick facts
| Lead sponsor | BioSensics |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 1 January 2026 |
| Primary completion | 31 December 2027 |
| Estimated completion | 30 April 2028 |
| Sites | 1 location across United States |
Conditions studied
- Myasthenia Gravis — all drugs for Myasthenia Gravis →
- Myasthenia Gravis, Generalized — all drugs for Myasthenia Gravis, Generalized →
Sponsor
BioSensics — full company profile →
Who can join
Adults 18 to 80, any sex, with Myasthenia Gravis or Myasthenia Gravis, Generalized. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Evaluate the feasibility of using digital health technologies to monitor symptoms in myasthenia gravis (MG). Study subjects will be screened and enrolled at Massachusetts General Brigham Hospital to participate in this 12 month observational study. Study subjects will be asked to wear multiple wearable sensors to monitor their physical activity and PPG during daily activities. Participants will also complete speech, video, and ePRO and eCOA digital assessments at home and during study visits. The primary objective for this observational study is to measure the correlation of sensor-derived measures of physical activity to MG-specific ratings of MG-ADL, QMG, MGC, and Neuro-QoL Fatigue
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07224386
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Myasthenia Gravis
Currently open trials in the same condition.
- NCT07478172 — Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease · NA · recruiting
- NCT07217587 — Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis · Phase 3 · recruiting
- NCT07284420 — ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With · Phase 2 · recruiting
- NCT07294170 — ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Particip · recruiting
- NCT07246564 — Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myastheni · Phase 4 · recruiting
Other BioSensics trials
Trials by the same sponsor.
- NCT07240805 — Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies · not yet recruiting
- NCT07333898 — Digital Measurements of Motor and Voice Functions in FTD · not yet recruiting
- NCT07315984 — Multi-Modal Digital Monitoring of Disease Symptoms Huntington's Disease · not yet recruiting
- NCT07226830 — Quantification of Change in MG Disease Activity in Individuals With Generalized Myasthenia Gravis (gMG) After Administra · not yet recruiting
- NCT03431025 — Wrist-worn Sensors for Tele-Rehabilitation of the Hemiparetic Upper Extremity · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07224386 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by BioSensics
- Last refreshed: 4 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07224386.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing